Résumé de l'étude

166 patients met eligibility criteria and were randomized to receive either parecoxib sodium 40 mg intravenously before skin incision or placebo normal saline. Follow-up was completed by 151 patients at 2 months and 150 patients at 6 months. The primary outcome of interest was the incidence of postoperative delirium within 48 hours, assessed using the Confusion Assessment Method–Chinese Reversion (CAM-CR). Secondary outcomes included delirium severity scores, postoperative pain measured using the Faces Pain Scale–Revised (FPS-R), and functional prognosis assessed using the Activities of Daily Living scale (ADL) at 2 and 6 months. Overall, the results of the study revealed that prophylactic parecoxib sodium significantly reduced both the incidence and severity of postoperative delirium compared with placebo, while not demonstrating measurable benefit on longer-term functional recovery.